Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer (NCT06532279)
A Randomized, Masked, Placebo Controlled, Phase II Trial Of Concurrent Chemoradiation With BMX-001 In Patients With Head And Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral mucositis (inflammation and mouth sores) is a common side effect of chemoradiation that can cause pain and difficulty swallowing. Usual management of these side effects typically consists of using mouth rinses and pain medications during treatment and for several weeks after completion of treatment. BMX-001 neutralizes harmful substances in the body, preventing damage to macromolecules such as DNA and minimizes free radical-related toxicity in normal tissues. Adding BMX-001 to usual symptom management may be more effective than usual symptom management alone at reducing oral mucositis in patients receiving chemoradiation for head and neck cancer.
Who can join: Review the eligibility criteria below.
Location: Arizona Center for Cancer Care - Gilbert — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (153 Sites)
Showing the first 25 of 153 sites.
- Arizona Center for Cancer Care - Gilbert — Gilbert, Arizona
- Arizona Center for Cancer Care-Peoria — Peoria, Arizona
- Arizona Center for Cancer Care - Phoenix — Phoenix, Arizona
- Arizona Center for Cancer Care - Scottsdale — Scottsdale, Arizona
- Arizona Center for Cancer Care-Surprise — Surprise, Arizona
- Arizona Center for Cancer Care — Tempe, Arizona
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
- Keck Medicine of USC Buena Park — Buena Park, California
- UC San Diego Health System - Encinitas — Encinitas, California
- UC San Diego Moores Cancer Center — La Jolla, California
- Los Angeles General Medical Center — Los Angeles, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California
- USC Norris Oncology/Hematology-Newport Beach — Newport Beach, California
- UC San Diego Medical Center - Hillcrest — San Diego, California
- Shaw Cancer Center — Edwards, Colorado
- George Washington University Medical Center — Washington D.C., District of Columbia
- Sarasota Memorial Hospital-Venice — N. Venice, Florida
- Moffitt Cancer Center at SouthShore — Ruskin, Florida
- Florida Cancer Specialists - Sarasota — Sarasota, Florida
- Florida Cancer Specialists - Sarasota Downtown — Sarasota, Florida
- Sarasota Memorial Hospital — Sarasota, Florida
- Sarasota Memorial Health Care Center at University Parkway — Sarasota, Florida
- Moffitt Cancer Center-International Plaza — Tampa, Florida
- Moffitt Cancer Center - McKinley Campus — Tampa, Florida
- Moffitt Cancer Center — Tampa, Florida
📞 Contact the Study Coordinator
Phone: (480) 278-8261
Email: penny.labriola@arizonaccc.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer — Atlanta, Georgia
- Swallowing Outcomes and Circulating Tumor DNA in Patients With HPV Related Oropharyngeal Cancer Treated With Transoral Surgery and Reduced Intensity Adjuvant Therapy — New Brunswick, New Jersey
- De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA — Scottsdale, Arizona
- Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin — Beverly Hills, California
- Evaluating a Decreased Dose of Radiation Therapy to the Elective Neck for the Treatment of HPV-Related Oropharyngeal Cancer, ENLIGHT Trial — Chicago, Illinois
Explore by condition: All Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.